As per MRFR analysis, the India Patient-Derived Xenograft Model Market Size was estimated at 11.3 (USD Million) in 2024. The India Patient-Derived Xenograft Model Market Industry is expected to grow from 12.8 (USD Million) in 2025 to 51.2 (USD Million) by 2035.
The India Patient-Derived Xenograft Model Market CAGR (growth rate) is expected to be around 13.431% during the forecast period (2025 - 2035).
The India Patient-Derived Xenograft (PDX) Model Market is witnessing significant growth driven by various key market drivers. The increasing prevalence of cancer in India, as highlighted in reports from the National Cancer Registry Programme, emphasizes the urgent need for better diagnostic and therapeutic options. The Indian government’s “National Health Mission” also aims to enhance healthcare delivery, which indirectly supports research in advanced therapeutic models such as PDX.
Moreover, collaborations between Indian biotech firms and international pharmaceutical companies are on the rise, promoting research and development in this area. Opportunities for growth exist, especially in sectors such as personalized medicine and targeted therapies. As healthcare in India evolves, there’s a growing need for models that can provide more accurate representations of human tumors, allowing for improved drug efficacy testing.
This presents a chance for Indian research institutions and companies to innovate and advance their capabilities in creating robust PDX models tailored to diverse patient demographics. In recent times, trends indicating a shift toward precision medicine are gaining traction in India. Studies reveal that there is increasing interest in the development of PDX models that reflect the multi-genomic nature of Indian cancer patients.
Additionally, funding for research and development in biomedicine, including PDX technologies, is witnessing a boost due to government incentives and health programs that promote innovative healthcare solutions. The rise of biobanking in India also enhances the PDX Model Market, as it supports the availability of diverse tumor samples for research. Furthermore, advancements in technology related to gene editing and molecular profiling are paving the way for more sophisticated PDX models, which essential for advancing cancer therapies.
Overall, these trends position the India Patient-Derived Xenograft Model Market for continued growth, emphasizing the importance of localized research and the need for tailored treatment approaches in the Indian healthcare landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rise in cancer cases in India has been a significant factor driving the growth of the India Patient-Derived Xenograft Model Market Industry. According to the National Cancer Registry Programme, there are over 1.16 million new cancer cases reported annually in India. This underscores the need for advanced research tools, including patient-derived xenograft models, which facilitate personalized medicine.
Major organizations such as the Indian Council of Medical Research (ICMR) have acknowledged the increasing burden of cancer, pushing for enhanced Research and Development (R&D) initiatives. These initiatives are critical for developing more effective therapeutic strategies, highlighting the increasing demand for patient-derived xenograft models in India.
The biopharmaceutical sector in India is experiencing significant growth, with the country being one of the largest producers of generic drugs globally. The Department of Pharmaceuticals reports an increase in biopharma research investments, with an expected rise in funding for innovative drug development. This scenario is creating a higher demand for patient-derived xenograft models, as they are crucial for validating therapeutic efficacy in preclinical studies.
BIRAC and other top organizations are fostering initiatives that promote the use of patient-derived models and drug discovery, which has been propelling the India Patient-Derived Xenograft Model Market Industry.
Technological advancements in cell culture techniques and genetic manipulation are significantly enhancing the efficacy of patient-derived xenografts. The Council of Scientific and Industrial Research (CSIR) has reported on the innovative developments in bioengineering that contribute to more accurate models reflecting patient tumors. These improvements are essential for obtaining precise data that drives the development of personalized medicine and targeted therapies.
As more research institutions in India adopt these advanced techniques, the demand for patient-derived xenograft models in the India Patient-Derived Xenograft Model Market Industry is expected to rise.
The Tumor Type segment of the India Patient-Derived Xenograft Model Market is crucial for understanding the dynamics of cancer research and treatment development in the country. As cancer rates rise, there is an increased focus on precision medicine and personalized treatment approaches, driving demand for patient-derived xenograft models which closely mimic human tumors. Lung cancer remains a significant concern, given high incidence and mortality rates associated with it in India.
The growth in research around this tumor type underscores the need for innovative therapies and effective drug testing. Likewise, pancreatic cancer, often diagnosed at advanced stages due to its subtle symptoms, poses challenges that necessitate tailored models to explore new therapeutic avenues. Prostate cancer, the most common cancer among men in India, is entering a phase of heightened research efforts as awareness and screening measures improve, leading to a greater emphasis on developing models that can accurately represent this malignancy.
Furthermore, breast cancer, which has seen increasing prevalence, is also a vital area of focus, as patient-derived xenografts can aid in studying tumor heterogeneity and treatment resistance. Other cancer types reveal a broad spectrum of research interests, reflecting the diverse oncological landscape in India. This segmentation illustrates the importance of niche research areas within the overall patient-derived xenograft framework, catering to the distinct biological behaviors and treatment challenges associated with each tumor type.
In this landscape, market growth and development in the India Patient-Derived Xenograft Model Market signify a collective effort towards enhancing cancer research, improving outcomes, and ultimately transforming therapeutic strategies tailored for the Indian population.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Model Type segment of the India Patient-Derived Xenograft Model Market is primarily categorized into Mice and Rats, both of which play distinct roles in preclinical research. Mice are favored for their small size, rapid life cycle, and genetic similarities to humans, making them ideal for various research and development purposes, especially in oncology and pharmacology. Their ease of handling and well-established genetic models further enhance their applicability in patient-derived xenograft applications.
On the other hand, Rats provide advantages in studies requiring larger body mass, notably in pharmacokinetic profiling and toxicology assessments. The use of Rats is significant due to their advanced cognitive abilities, which make them suitable for neurological studies. As the pharmaceutical and biotechnological industries in India continue to expand, the demand for these model types remains robust, driven by the need for more effective drug development and personalized medicine.
The growth of research institutions and the increasing focus on innovation in treatment modalities underscore the critical importance of these models in India’s evolving biomedical landscape. Overall, the emphasis on both Mice and Rats highlights their complementary roles in enhancing the efficiency and accuracy of preclinical testing.
The India Patient-Derived Xenograft Model Market, particularly in the End-User segment, showcases a diverse landscape crucial for advancing healthcare solutions. Pharmaceutical and biopharmaceutical companies are at the forefront, leveraging patient-derived models to optimize drug development and enhance targeted therapies. Their significant investment in Research and Development activities drives innovation, leading to improved therapeutic outcomes.
Academic and research institutes also play a pivotal role, focusing on fundamental research and novel therapies that utilize these xenograft models to study disease mechanisms and treatment responses. Clinical Research Organizations (CROs) contribute by providing specialized services that facilitate the efficient management of clinical trials involving these models, which accelerates the drug development process. Contract Development and Manufacturing Organizations (CDMOs) support these end-users by offering scalable production techniques that meet regulatory standards.
The ongoing trend towards personalized medicine and the rise in chronic diseases in India are key growth drivers, enhancing the demand for patient-derived xenograft models across various applications in the healthcare sector. With a robust increase in investment in biotechnology and active collaborations between industry and academia, the India Patient-Derived Xenograft Model Market is positioned for significant growth in the foreseeable future.
The India Patient-Derived Xenograft Model Market has witnessed significant growth and development, characterized by both emerging and established entities navigating a complex landscape of biomedical research and drug development. This market is driven by the increasing demand for personalized medicine, cancer research, and drug screening processes that require advanced in vivo models for efficacy and safety studies. A pivotal factor influencing competition is the innovation of technologies that facilitate the creation of more representative and reliable patient-derived xenograft models, which enhance the translational value of preclinical research.
Companies in this market are focusing on partnerships, strategic acquisitions, and collaborations with research institutions to leverage expertise and enhance their product portfolios, thus fostering a competitive edge in the evolving healthcare ecosystem in India. Bioneer Corporation has established a noteworthy presence in the India Patient-Derived Xenograft Model Market. The company leverages its capabilities in molecular biology and biotechnology to offer unique solutions tailored for cancer research through PDX models.
Bioneer's strength lies in its commitment to high-quality research outputs and its robust network within the scientific community, positioning it well against competitors. The company's focus on developing innovative models and dedicated customer support also contributes to its competitive advantage, making it a trusted choice among researchers and clinical institutions exploring patient-specific treatment options in India. This focus on innovation and customer engagement allows Bioneer Corporation to strengthen its foothold in the market.
Horizon Discovery operates effectively within the India Patient-Derived Xenograft Model Market by delivering essential tools and services that aid scientific research and drug development. The company offers a diversified portfolio that includes genetically engineered cell lines and advanced PDX models, enhancing its market presence significantly. Horizons' strengths are highlighted through its strong emphasis on innovation, high-quality product offerings, and a commitment to addressing specific research needs within the Indian market context.
The company has also engaged in strategic partnerships and collaborations, enhancing its capabilities and expanding its reach in terms of customer engagement. Additionally, any mergers and acquisitions pursued by Horizon Discovery further solidify its position and enable it to enhance its product offerings to the unique needs of the Indian healthcare landscape, driving greater advancements in personalized medicine and research outcomes.
Recent developments in the India Patient-Derived Xenograft Model Market have seen notable growth due to advancements in cancer research and personalized medicine. Companies such as Bioneer Corporation and Horizon Discovery continue to innovate, enhancing the accuracy of xenograft models for preclinical studies. In September 2022, Celerion expanded its services in India, catering to the growing demand for patient-derived models, while Crown Bioscience reported increased collaborations with Indian biotech firms to enhance their R&D capabilities.
Notable mergers and acquisitions include Thermo Fisher Scientific's acquisition of a biotech firm in July 2023, which complements its patient-derived xenograft portfolio. This move has been viewed positively, leading to a boost in stock valuation for Thermo Fisher Scientific as it enhances its market share within India. Additionally, Eli Lilly and Company has initiated partnerships with local research institutions to further develop their patient-derived models, reflecting the growing emphasis on localized solutions.
The market has been influenced significantly over the last two years, with increased investments and governmental support for biomedical research contributing to an expanding landscape for patient-derived xenograft technologies in India.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 11.3(USD Million) |
| MARKET SIZE 2024 | 12.8(USD Million) |
| MARKET SIZE 2035 | 51.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.431% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Bioneer Corporation, Horizon Discovery, Celerion, Crown Bioscience, Avantor, Thermo Fisher Scientific, R&D Systems, BristolMyers Squibb, Charles River Laboratories, MedImmune, JAX Laboratories, Genentech, The Jackson Laboratory, Eli Lilly and Company |
| SEGMENTS COVERED | Tumor Type, Model Type, End-User |
| KEY MARKET OPPORTUNITIES | Growing cancer research funding, Rising demand for personalized medicine, Advancements in PDX technology, Increase in biotech collaborations, Expanding drug development pipelines |
| KEY MARKET DYNAMICS | Rising cancer research funding, Increasing demand for personalized medicine, Technological advancements in xenografts, Growing prevalence of chronic diseases, Collaborative research initiatives in healthcare |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The projected market size for the India Patient-Derived Xenograft Model Market in 2024 is valued at 12.8 million USD.
By 2035, the India Patient-Derived Xenograft Model Market is expected to reach a value of 51.2 million USD.
The expected CAGR for the India Patient-Derived Xenograft Model Market from 2025 to 2035 is 13.431%.
In 2024, the Lung Cancer segment leads the India Patient-Derived Xenograft Model Market with a value of 3.5 million USD.
The Pancreatic Cancer segment is expected to be valued at 10.2 million USD by 2035.
Key players in the India Patient-Derived Xenograft Model Market include Bioneer Corporation, Horizon Discovery, Celerion, and Thermo Fisher Scientific among others.
In 2024, the Prostate Cancer segment is projected to be valued at 2.2 million USD.
By 2035, the Breast Cancer segment is expected to generate a market value of 11.8 million USD.
Other Cancer types in the India Patient-Derived Xenograft Model Market are valued at 1.9 million USD in 2024.
Emerging trends in the India Patient-Derived Xenograft Model Market include increased research in personalized medicine and advancements in cancer therapies.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
